Ignite Creation Date:
2024-05-06 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03543969
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2018-05-21
Brief Title:
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot early phase I trial studies how well encorafenib binimetinib and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth Immunotherapy with nivolumab may induce changes in bodys immune system and may interfere with the ability of tumor cells to grow and spread Giving encorafenib binimetinib and nivolumab may kill more tumor cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None